Our first webinar of this two-part Advanced Practice Provider webinar series is Monday: Understanding Genomic Risk: Navigating High and Low-Risk Breast Cancer Profiles Dates: July 28 & August 4 Time: 12:00–12:30 PM ET Register today: 28th: ow.ly/IFL150WjPhA

✈️ Just like in Top Gun, the best results come from teamwork, strategy, and fearless execution. 🕶️ We brought the Mavericks of the Western Sales team together last week to share wins (and lessons learned) and focused our targets with the precision of fighter pilots. In sales,

✨“MammaPrint helps identify tumors more likely to respond to chemotherapy,” says Dr. Rita Mukhtar. ✨ Discover the 2025 #I-SPY2Trial’s breakthrough in breast cancer treatment! In this interview from her #ASBrS2025 presentation, Rita Mukhtar, MD, breast surgeon at UCSF, dives

Join Us Live! Illuminating Tumor Biology New MammaPrint® + BluePrint® Insights from the 2025 ASCO Annual Meeting to Optimize Breast Cancer Care 📅 Date: Thursday August 14th, 2025 🕐 Time: 4-5pm EST 💻 Live Webinar – 1 hour Hear directly from experts: 👨‍⚕️ Dr. Adam Brufsky 👩‍⚕️

👩‍⚕️Dr. Erin Cobain, University of Michigan #RogelCancerCenter is the principal investigator of #SWOG Cancer Research Network Trial S2206. Watch her presentation to learn about the trial and how retrospective data from Agendia’s I-SPY 2 clinical trial contributed to its inception.

💻 Join us for the second of our two-part Advanced Practice Provider webinar series on Monday - Understanding Genomic Risk: Navigating High and Low-Risk Breast Cancer Profiles 📅Date: August 4 🕛Time: 12:00–12:30 PM ET Register today: ow.ly/6rk650WjPhz If you missed the

By illuminating tumor biology alongside traditional factors, MammaPrint® + BluePrint® deliver multiple treatment answers in just 6 days—empowering precise, timely decisions for every patient, at every stage, regardless of age, race, or ethnicity. youtu.be/uUxxz7zs7Ng

💔**Navigating Grief in Healthcare: A Vital Conversation** In the demanding field of oncology, healthcare professionals often face the heavy burden of patient suffering and loss. A recent podcast, featuring Drs. Hope Rugo, Sheri Brenner, and Mikolaj Slawkowski-Rode, sheds light

💡What if ONE genomic test platform could answer MULTIPLE critical questions at initial consult and deliver results in just 6 days* for your early-stage breast cancer patients? With #MammaPrint and #BluePrint, it can. ⏱️Results available in 6 days* ✅ More than just chemo/no

🧬 𝗜𝗹𝗹𝘂𝗺𝗶𝗻𝗮𝘁𝗶𝗻𝗴 𝘁𝘂𝗺𝗼𝗿 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 👉 𝗡𝘂𝗲𝘃𝗼𝘀 𝗵𝗮𝗹𝗹𝗮𝘇𝗴𝗼𝘀 𝗱𝗲 𝗠𝗮𝗺𝗺𝗮𝗣𝗿𝗶𝗻𝘁 + 𝗕𝗹𝘂𝗲𝗣𝗿𝗶𝗻𝘁 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝗱𝗼𝘀 𝗲𝗻 𝗹𝗮 𝗥𝗲𝘂𝗻𝗶𝗼́𝗻 𝗔𝗻𝘂𝗮𝗹 𝗔𝗦𝗖𝗢 𝟮𝟬𝟮𝟱 No te pierdas este webinar en el que tres oncólogos expertos en

One week away - Join Us Live! Illuminating Tumor Biology New MammaPrint® + BluePrint® Insights from the 2025 ASCO® Annual Meeting to Optimize Breast Cancer Care 📅 Date: Thursday August 14th, 2025 🕐 Time: 4-5pm EST 💻 Live Webinar – 1 hour Hear directly from experts: 👨‍⚕️ Dr.

🎗 In this article, we share how breast cancer treatment isn't one-size-fits-all, and thanks to genomic testing, it doesn't have to be. Women can make more informed, personalized decisions about their care, minimizing unnecessary treatments and side effects. 🔬 Learn how

🪓💪 This week, our Southeast Sales Team held their regional sales meeting filled with strategy, collaboration, and a little friendly competition! Taking a break from a usual dinner, they headed out for a lively axe throwing session. Not only did they sharpen their skills (both

NEW PUBLICATION: "MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data" New data from the FLEX Study published in the JNCI Cancer Spectrum by Brufsky el al., confirm that MammaPrint is predictive of both DRFI prognosis and

Tomorrow - Join Us Live! Illuminating Tumor Biology New MammaPrint® + BluePrint® Insights from the 2025 ASCO Annual Meeting to Optimize Breast Cancer Care 📅 Date: Thursday August 14th, 2025 🕐 Time: 4-5pm EST 💻 Live Webinar – 1 hour Hear directly from experts: 👨‍⚕️ Dr. Adam

MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer cancernetwork.com/view/mammaprin… via CancerNetwork®

Agendia's genomic test shows promise in guiding chemotherapy use for early breast cancer firstwordpharma.com/story/5988629 via FirstWord Pharma

📣We are excited to announce the publication of new findings in @JNCI_NOW Cancer Spectrum validating the predictive utility of the MammaPrint 70-gene assay for chemotherapy benefit in patients with hormone receptor-positive, HER2-negative (HR+HER2-) early-stage breast cancer.

🔬 Clinical evidence demonstrates that MammaPrint® is predictive of adjuvant as well as neoadjuvant chemotherapy benefit. Real-world evidence from the FLEX Study shows that MammaPrint and BluePrint can identify which HR+/HER2– early-stage breast cancer patients are most likely